Skip to main content
Top

Drugs

Issue 5/2023

Content (9 Articles)

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation

  • Open Access
  • Review Article

Nanthini Jayabalan, Bryan Oronsky, Pedro Cabrales, Tony Reid, Scott Caroen, Aishwarya M. Johnson, Natalia A. Birch, John D. O’Sullivan, Richard Gordon

Aspirin for the Prevention of Early and Severe Pre-Eclampsia Recurrence: A Real-World Population-Based Study

Grégory Lailler, Clémence Grave, Amélie Gabet, Nolwenn Regnault, Catherine Deneux-Tharaux, Sandrine Kretz, Vassilis Tsatsaris, Geneviève Plu-Bureau, Jacques Blacher, Valérie Olie

Teplizumab: First Approval

Susan J. Keam

Bexagliflozin: First Approval

Sheridan M. Hoy

Ublituximab: First Approval

Arnold Lee

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images